CG Oncology (CGON) Intangibles (2025 - 2026)
CG Oncology (CGON) reported Intangibles of $560000.0 for Q1 2026, down 2.61% quarter-over-quarter from $575000.0 in Q4 2025.
CG Oncology (CGON) Intangibles (2025 - 2026) Analysis & Trends
CG Oncology has reported Intangibles for 2 years, with the latest figure at $560000.0 in Q1 2026.
- For the quarter ending Q1 2026, Intangibles changed N/A year-over-year to $560000.0; the trailing twelve-month figure through Mar 2026 stood at $560000.0 (changed N/A YoY), and the FY2025 full-year result was $575000.0, changed N/A from the prior year.
- Intangibles for Q1 2026 stood at $560000.0, down from $575000.0 in the prior quarter.
- The five-year high for Intangibles was $1.7 million in Q3 2025, with the low at $560000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.41 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 418.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 7.73 Mn |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | 560,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 560,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 1.70 Mn |